Completed PHASE3 INTERVENTIONAL 4-arm NCT01712516

A 12-week Treatment, Multi-center, Randomized, Double-blind, Parallel-group, Placebo and Active Controlled Study to Assess the Efficacy, Safety, and Tolerability of Indacaterol Maleate / Glycopyrronium Bromide in COPD Patients With Moderate to Severe Airflow Limitation

Sponsor: Novartis Pharmaceuticals

Conditions Chronic Obstructive Pulmonary Disease (COPD)

Interventions NVA237 Placebo QAB149 QVA149

Updated 7 times since 2017 Last updated: Jul 13, 2015 Started: Dec 31, 2012 Primary completion: Feb 28, 2014 Completion: Feb 28, 2014

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01712516, this PHASE3 trial focuses on Chronic Obstructive Pulmonary Disease (COPD) and remains completed. Sponsored by Novartis Pharmaceuticals, it has been updated 7 times since 2012, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

7 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Completed PHASE3
Jan 2017 — Feb 2017 [monthly]

Completed PHASE3

First recorded

Dec 2012

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Novartis Pharmaceuticals

Data source: Novartis

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

*See Various Dept.'s*, United States , Alexandria, Egypt , Arlington, United States , Armenia, Colombia , Balassagyarmat, Hungary , Bardejov, Slovakia , Barranquilla, Colombia , Beuvry, France , Bojnice, Slovakia , Brandon, United States and 74 more locations